MacroGenics Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Expansion Decisions with the Full Report
This MacroGenics Balanced Scorecard Analysis gives you a clear, company-specific view of the firm's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Benefits
Clinical Milestones
Clinical Milestones turn MacroGenics' pipeline into a clear operating dashboard, with each program tracked against enrollment, safety, and efficacy gates. In fiscal 2025, that matters because the company is still clinical-stage and reported a net loss of "$124.7 million" in 2024, so progress has to be visible and disciplined. One clean line: milestone hits make the science easier to manage and the story easier to defend.
DART Productivity
DART productivity shows whether MacroGenics' Dual-Affinity Re-Targeting platform is producing differentiated 2-target candidates with real therapeutic value, not just trial headlines. It keeps the focus on pipeline output, advancement rate, and pipeline depth, so management can judge platform quality. In 2025, that matters because each new DART asset must justify R&D spend and add clear clinical and commercial upside.
Capital Discipline
Capital discipline gives MacroGenics management a cleaner way to rank programs by probability-adjusted value, burn, and timing. That matters because in biotech, a 1-quarter slip in data can move valuation more than broad market swings. It also helps protect cash for the highest-conviction assets and avoid funding weak shots.
Partner Visibility
Partner visibility lets MacroGenics track collaboration strength, licensing progress, and outside validation from pharma partners. In biotech, those signals can matter before sales arrive, because a signed alliance or milestone update can support credibility, pipeline de-risking, and funding access. It also gives investors a clean read on how well the company can turn science into partner-backed value.
Cross-Team Alignment
Cross-Team Alignment keeps MacroGenics R&D, regulatory, manufacturing, and finance focused on the same Balanced Scorecard goals, so the clinical plan, CMC work, and budget move together. That cuts the risk of one team hitting its own KPI while the program slips on timing, cost, or filing readiness. For a development-stage biotech, that kind of alignment can save months of rework and protect capital.
MacroGenics 2025: Sharper Pipeline Picks, Smarter Cash Use
MacroGenics' 2025 benefits are sharper decision-making, faster pipeline pruning, and better cash use. With a 2024 net loss of "$124.7 million", the scorecard helps management protect capital while pushing only the strongest clinical and DART assets.
| Benefit | 2025 readout |
|---|---|
| Capital discipline | Rank by burn and value |
| Clinical milestones | Track safety and efficacy gates |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Binary Readouts
Binary readouts can distort MacroGenics Balanced Scorecard because one Phase 1 or Phase 2 oncology result can outweigh months of process metrics. In biotech, a single go or no-go data point often drives the story more than quarterly execution.
That makes the scorecard noisy: a strong 1 trial can lift sentiment fast, while one weak readout can erase progress across pipeline, cash use, and partnering.
For MacroGenics, this means the downside is not missing activity, but letting one clinical number dominate the whole view.
Slow Feedback
Slow feedback is a real drawback for MacroGenics because clinical development moves in months and quarters, not weeks. A Phase 2 or Phase 3 readout can take 12 to 24 months from enrollment to final analysis, so a balanced scorecard may lag the true trial picture. That delay can hide shifts in response rates, safety signals, or dropout trends until the next data cut.
Thin Commercial Data
MacroGenics still has thin commercial data in FY2025 because it has no broad product-sales base yet, so customer counts, repeat-buy rates, and unit economics stay limited. That makes the financial leg of the Balanced Scorecard lighter than R&D and pipeline metrics, even though the company reported $0 in product revenue. Until a drug scales commercially, most value signals come from trials, milestones, and cash burn, not customer data.
Cash Pressure
MacroGenics' Cash Pressure comes from high R&D burn, so operating cash can get used faster than scorecard gains show. Its 2024 filing showed $196.9 million in cash, cash equivalents, and marketable securities, plus a $97.9 million net loss, which means financing needs can stay front and center. If capital markets tighten in 2025, liquidity planning can matter more than strategic metrics.
Small-Sample Noise
Small-sample noise is a real weakness for MacroGenics because early oncology cohorts often include only about 10 to 30 patients, so one or two responders can make the scorecard look much stronger than the true trend. The same is true for safety: a single serious adverse event can swing the readout and overstate risk. Until a larger 2025 dataset is built, these early signals should be treated as directional, not definitive.
MacroGenics: One Small Readout Can Override the Whole Story
MacroGenics' main drawback is that one oncology readout can swamp the whole Balanced Scorecard, so a Phase 1 or Phase 2 signal can overrule pipeline and execution metrics. Small cohorts of 10 to 30 patients also make efficacy and safety swings look bigger than they are.
| Drawback | FY2025/Latest |
|---|---|
| Revenue base | $0 product revenue |
| Liquidity | $196.9M cash, 2024 filing |
| Net loss | $97.9M |
Get Your Copy
MacroGenics Reference Sources
This preview shows the actual MacroGenics Balanced Scorecard analysis document you'll receive after purchase – no sample, no placeholders. The full report is the same professional, structured file shown here, with complete insights and analysis. Once you complete your purchase, the full version is unlocked for immediate download.
Frequently Asked Questions
It should emphasize clinical execution and capital efficiency. MacroGenics is a clinical-stage oncology company built around a 2-target DART platform, so the most useful measures are Phase 1/2/3 progress, enrollment pace, and quarterly cash use. The 4 scorecard perspectives help management avoid overreacting to a single trial data point.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.